Show simple item record

dc.contributor.authorMonk, BJ
dc.contributor.authorSmith, G
dc.contributor.authorLima, J
dc.contributor.authorLong, GH
dc.contributor.authorAlam, N
dc.contributor.authorNakamura, H
dc.contributor.authorMeulendijks, D
dc.contributor.authorGhiorghiu, D
dc.contributor.authorBanerjee, S
dc.date.accessioned2022-04-27T12:30:23Z
dc.date.available2022-04-27T12:30:23Z
dc.identifier.citationGynecologic oncology, 2022, 164 (2), pp. 325 - 332en
dc.identifier.issn0090-8258
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5103
dc.identifier.eissn1095-6859en_US
dc.identifier.eissn1095-6859
dc.identifier.doi10.1016/j.ygyno.2021.12.008en_US
dc.identifier.doi10.1016/j.ygyno.2021.12.008
dc.description.abstract<h4>Objectives</h4>To characterize clinical outcomes of women with advanced/recurrent endometrial cancer (AEC) in routine practice using electronic health records from a real-world database.<h4>Methods</h4>Adult women diagnosed with AEC (stage III/IV, or early stage with locoregional/distant recurrence) between January 1, 2013 and September 30, 2020, inclusive, were eligible provided they received platinum-based chemotherapy at any time following diagnosis and had ≥2 clinical visits. Follow-up was from initiation of systemic treatment after advanced diagnosis (index) until March 30, 2021, last available follow-up, or death, whichever occurred first. Outcomes, by histological subtype, included Kaplan-Meier estimates of overall survival (OS) and time to first subsequent therapy or death (TFST).<h4>Results</h4>Of the 2202 women with AEC, most were treated in a community setting (82.7%) and presented with stage III/IV disease at initial diagnosis (74.0%). The proportion with endometrioid carcinoma, uterine serous carcinoma (USC), and other AEC subtypes was 59.8%, 25.0%, and 15.2%, respectively. The most common first systemic treatment following advanced/recurrent diagnosis was platinum-based combination chemotherapy (82.0%). Median OS (95% CI) from initiation of first systemic treatment was shorter with USC (31.3 [27.7-34.3] months) and other AECs (29.4 [21.4-43.9] months) versus endometrioid carcinoma (70.8 [60.5-83.2] months). Similar results were observed for TFST. Black/African American women had worse OS and TFST than white women.<h4>Conclusions</h4>Women with AEC had poor survival outcomes, demonstrating the requirement for more effective therapies. To our knowledge, this is the most comprehensive evaluation of contemporary treatment of AEC delivered in a community setting to date.en_US
dc.formatPrint-Electronicen_US
dc.format.extent325 - 332en_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectHumansen_US
dc.subjectCarcinoma, Endometrioiden_US
dc.subjectNeoplasms, Cystic, Mucinous, and Serousen_US
dc.subjectEndometrial Neoplasmsen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectNeoplasm Stagingen_US
dc.subjectHysterectomyen_US
dc.subjectSurvival Rateen_US
dc.subjectRetrospective Studiesen_US
dc.subjectCohort Studiesen_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectAfrican Americansen_US
dc.subjectUnited Statesen_US
dc.subjectFemaleen_US
dc.subjectElectronic Health Recordsen_US
dc.subjectKaplan-Meier Estimateen_US
dc.subjectAntineoplastic Agents, Immunologicalen_US
dc.subjectWhitesen_US
dc.titleReal-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.en
dc.typeJournal Article
dcterms.dateAccepted2021-12-04
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1016/j.ygyno.2021.12.008en
dc.relation.isPartOfGynecologic oncologyen_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume164en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorBanerjee, Susanaen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/